ADOPT PGx recently celebrated reaching its participant enrollment milestone in September 2023 following the enrollment of 4,111 total participants. The last participant should complete the follow-up period for the trial by April 2024.

The primary goal of the study is to reduce depression symptoms and improve pain control in participants who are expected to process anti-depressant or pain medications faster or slower than normal as indicated by pharmacogenetic testing. Secondary goals include safety endpoints, changes in overall well-being, and differences in healthcare utilization.

The study is an umbrella protocol comprised of three separate arms: Acute Pain, including 1,602 participants, Chronic Pain, which enrolled 1,461 participants, and Depression, including 1,408 participants.

ADOPT PGx was conducted across five clinical groups representing nine different healthcare institutions in the United States.

Participants were randomized in a 1:1 ratio to immediate versus delayed pharmacogenetic testing and return of results to participants and providers.

Study results and primary manuscripts are expected to be completed in late 2024.

For more information about each of the trials, visit their trial page: Acute Pain, Chronic Pain, and Depression.